Elevated Plasma Levels of TGF-β in Melanoma Patients
Author Information
Author(s): K Krasagakis, D Tholke, B Farthmann, J Eberle, U Mansmann, CE Orfanos
Primary Institution: University Medical Center Benjamin Franklin, The Free University of Berlin
Hypothesis
Do patients with malignant melanoma have elevated circulating levels of TGF-β isoforms and is there an association with tumor progression?
Conclusion
The study found significantly elevated levels of TGF-β1 and TGF-β2 in patients with disseminated melanoma, indicating a potential link to advanced disease progression.
Supporting Evidence
- TGF-β1 levels were 4.2 times higher in patients with disseminated melanoma compared to controls.
- TGF-β2 levels were 1.5 times higher in patients with disseminated melanoma compared to controls.
- No significant difference in TGF-β3 levels was found between melanoma patients and controls.
Takeaway
This study shows that people with advanced melanoma have higher levels of certain proteins in their blood that might help the cancer grow.
Methodology
Blood samples were collected from 25 melanoma patients and 12 healthy volunteers, and plasma levels of TGF-β isoforms were measured using ELISA.
Limitations
The study did not assess the functional implications of elevated TGF-β levels on immune response.
Participant Demographics
25 malignant melanoma patients (13 with locoregional disease and 12 with distant metastasis) and 12 healthy volunteers.
Statistical Information
P-Value
0.0094 for TGF-β1 and 0.012 for TGF-β2 in disseminated melanoma patients
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website